Overview
- The suit seeks to represent investors who bought Ardelyx stock between January 13, 2025 and August 6, 2026 and alleges the company made false or misleading statements about two core drugs, XPHOZAH and IBSRELA.
- Plaintiffs say Ardelyx concealed payer and reimbursement barriers—specifically tighter prior-authorization and step-edit requirements—that delayed new-patient starts and slowed prescription fulfillment.
- According to the filings, Ardelyx cut full-year 2026 IBSRELA guidance and withdrew long-term XPHOZAH guidance on August 6, 2026, and the stock fell about 18% the next trading day, which plaintiffs identify as the market disclosure of the problem.
- The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5, and several plaintiff-side firms are soliciting affected investors ahead of the November 16, 2026 lead-plaintiff deadline.
- The case is at an early procedural stage: no class has been certified, investors are not represented unless they retain counsel or a lead plaintiff is appointed, and a ruling on lead counsel and certification will shape who directs the litigation and whether absent shareholders are bound by any outcome.